ECOG-ACRIN EAY131-H

Primary Category:

Treatment Protocols

Disease Category:

Molecular Profiling

Status:

Open

MATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma and Thyroid Cancer)

 

(See required screening study ECOG-ACRIN EAY131)

EAY131-H has expanded its accrual goal, therefore it is reactivated effective 10/02/2020.

NCT#02465060